Search

everythinglearnresearchcommunity

for

Search:↓

Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

No FDA-approved treatments for chemotherapy-induced hair loss existed in 2006; more research was needed.

The document concluded that FDA-approved treatments like minoxidil and finasteride are effective for hair loss, while the effectiveness of natural remedies and other non-approved treatments is not well-supported by evidence.

Finasteride, a hair loss drug, has unaddressed sexual side effects due to the manufacturer's inadequate safety measures and lack of additional studies.

Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.

New treatments for male hair loss are being explored to improve effectiveness and reduce side effects.

The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.

Digoxin is linked to a higher risk of anemia in patients with atrial fibrillation and heart failure.

The document concludes that proper diagnosis and FDA-approved treatments for different types of hair loss exist, but treatments for severe cases often fail and future improvements may focus on hair follicle stem cells.

Scalp cooling is the most effective FDA-approved method to prevent chemotherapy-induced hair loss, but more research is needed for other treatments.

Minoxidil and finasteride are the main FDA-approved treatments for hair loss, with other methods showing promise but lacking strong evidence.

Certain medications, especially 5-α reductase inhibitors and neuropsychiatric drugs, are often linked to erectile dysfunction.

Certain drugs, especially those for eyes, bacterial infections, imaging tests, and skin conditions, are more likely to cause itching, with differences seen across gender, age, and weight.

Cetuximab often causes skin rashes, and managing these is important for cancer treatment.

17α-estradiol is a safe estrogen that might protect the brain and doesn't cause feminization, needing more research for treating brain diseases.

Testosterone therapy can safely and effectively treat symptoms like low libido and fatigue in women, especially after menopause.

Current and new treatments for hair loss include topical minoxidil and oral finasteride, but results vary and new options are being explored.

JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.

Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.

Computer-aided methods can speed up COVID-19 drug discovery and help find new uses for existing drugs.

Minoxidil helps treat pattern hair loss in both men and women.

LLLT helps treat hair loss by increasing blood flow, reducing inflammation, and stimulating growth factors.

Finasteride's effectiveness on the frontal hair loss area is not well-studied or confirmed.

Clascoterone and minocycline are effective acne treatments with quick results and fewer side effects.

Choose between topical and oral minoxidil for hair growth based on personal tolerance and side effects.

New treatments for hair loss are being developed using molecular biology.

Some drugs have gained approval for new uses, while others like tricyclic antidepressants and aspirin show promise but aren't yet approved for these uses.

Current treatments for androgenetic alopecia are complex and promising, but more research is needed.